ACR: Ratio of Omega-6 to Omega-3 Affects Outcomes in SLE
MONDAY, Nov. 6, 2017 -- For patients with systematic lupus erythematosus (SLE), increasing omega 6 (n-6)-to-omega-3 (n-3) fatty acid ratios are associated with disease activity, and low vitamin D is associated with later total organ and renal damage, according to two studies presented at the annual meeting of the American College of Rheumatology, being held Nov. 3 to 8 in San Diego.
Prae Charoenwoodhipong, from the University of Michigan School of Public Health in Ann Arbor, and colleagues examined the correlation between dietary intake of n-3 and n-6 fatty acids and patient-reported outcomes in SLE in a cross-sectional study based on the MILES Program. The researchers found that increased n-6:n-3 ratios were associated with SLE disease activity after adjustment for covariates (Systemic Lupus Activity Questionnaire score, β 0.322). N-3 fatty acid intake was significantly correlated with better sleep quality (β −1.114) and trended toward significant decreases in depressive symptoms and presence of comorbid fibromyalgia.
Michelle A. Petri, M.D., Ph.D., from Johns Hopkins University School of Medicine in Baltimore, and colleagues examined whether vitamin D insufficiency/deficiency predicts later organ damage among patients with SLE. A total of 1,392 patients were included in the analysis. The researchers found that low vitamin D was associated with significantly increased risk of total organ damage and renal damage (adjusted relative risks, 1.17 and 1.66).
"Vitamin D supplementation, which can reduce proteinuria, should be a part of the treatment plan for lupus nephritis patients," Petri said in a statement.
One author from the Petri study disclosed financial ties to the pharmaceutical industry.
© 2020 HealthDay. All rights reserved.
Posted: November 2017
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.